Atezolizumab Combo Results in Intracranial Activity in BRAFV600+ Melanoma
Source: Cancer Network, September 2023
Second-line end points of the TRICOTEL trial assessing atezolizumab plus vemurafenib and cobimetinib in melanoma with central nervous system metastases appear consistent with primary efficacy end points.
A triplet regimen consisting of atezolizumab (Tecentriq) plus vemurafenib (Zelboraf) and cobimetinib (Cotellic) demonstrated intracranial activity in a population of patients with BRAFV600–mutant melanoma and central nervous system (CNS) metastases, according to data from the phase 2 TRICOTEL trial (NCT03625141).
For patients with BRAFV600–positive and wild-type disease, the overall response rate (ORR) by investigator assessment was 42% (95% CI, 29%-54%) and 27% (95% CI, 8%-55%), respectively, with a median follow-up of 9.7 months (Interquartile range [IQR], 6.3-15.0) and 6.2 months (IQR, 3.5-23.0).